The Pathology of Atherosclerosis: Plaque Development and Plaque Responses to Medical Treatment

American Journal of Medicine

Volumn 122, Issue 1 SUPPL., 2009, Pages

  Insull Jr , William ^a  

^a Section of Atherosclerosis and Vascular Medicine   (United States)

Author keywords

Atherosclerosis; Inflammation; Plaque

Indexed keywords

CYCLOOXYGENASE 2; FAT DROPLET; GELATINASE A; GELATINASE B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADAPTIVE IMMUNITY; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROGENESIS; ATHEROMA; ATHEROSCLEROTIC PLAQUE; CAUSE OF DEATH; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY OBSTRUCTION; CORONARY RISK; DISEASE COURSE; DISEASE PREDISPOSITION; FOAM CELL; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; INNATE IMMUNITY; LIPID STORAGE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK REDUCTION; SMOOTH MUSCLE FIBER; SUDDEN DEATH; THERAPY EFFECT; TISSUE SECTION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ANTICHOLESTEREMIC AGENTS; ARTERIAL OCCLUSIVE DISEASES; ATHEROSCLEROSIS; CHOLESTEROL; DIABETES MELLITUS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; OBESITY; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TOBACCO USE DISORDER; VENOUS THROMBOSIS;

EID: 57749092004     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2008.10.013     Document Type: Article

References (48)

1. McGill Jr. H.C. The geographic pathology of atherosclerosis. Lab Invest 18 theme issue (1968) 465-653
2. Stary H.C. The sequence of cell and matrix changes in atherosclerotic lesions of coronary arteries in the first forty years of life. Eur Heart J 11 suppl E (1990) 3-19
3. Shattock S.G. A report upon the pathological condition of the aorta of King Menephtah, traditionally regarded as the Pharaoh of the Exodus. Proc R Soc Med 2 Pathol Sect (1909) 122-127
4. Sun J., Sukhova G.K., Wolters P.J., et al. Mast cells promote atherosclerosis by releasing proinflammatory cytokines. Nat Med 13 (2007) 719-724
5. Deguchi J.O., Aikawa M., Tung C.H., et al. Inflammation in atherosclerosis: visualizing matrix metalloproteinase action in macrophages in vivo. Circulation 114 (2006) 55-62
6. Rosenfeld M.E., and Schwartz S.M. The Vulnerable Atherosclerotic Plaque: Strategies for Diagnosis and Management. In: Virmani R., Narula J., Leon M.B., and Willerson J.T. (Eds). Murine models of advanced atherosclerosis (2007), Blackwell Publishing, Malden, MA 105-127
7. Libby P., and Theroux P. Pathophysiology of coronary artery disease. Circulation 111 (2005) 3481-3488
8. Willerson J.T., and Ridker P.M. Inflammation as a cardiovascular risk factor. Circulation 109 suppl 1 (2004) II2-II10
9. Paoletti R., Gotto Jr. A.M., and Hajjar D.P. Inflammation in atherosclerosis and implications for therapy. Circulation 109 suppl 1 (2004) III20-III26
10. Hansson G.K. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 21 (2001) 1876-1890
11. Stary H.C. Atlas of Atherosclerosis: Progression and Regression. 2nd ed. (2003), Parthenon Publishing Group, New York
12. Virmani R., Kolodgie F.D., Burke A.P., Farb A., and Schwartz S.M. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 20 (2000) 1262-1275
13. Burke A.P., Kolodgie F.D., Farb A., Weber D.K., Malcom G.T., Smialek J., and Virmani R. Healed plaque ruptures and sudden coronary death: evidence that subclinical rupture has a role in plaque progression. Circulation 103 (2001) 934-940
14. Strong J.P., Malcom G.T., McMahan C.A., Tracy R.E., Newman III W.P., Herderick E.E., and Cornhill J.F. Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study. JAMA 281 (1999) 727-735
15. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Natural history of aortic and coronary atherosclerotic lesions in youth: findings from the PDAY study. Arterioscler Thromb 13 (1993) 1291-1298
16. Eggen D.A., and Solberg L.A. Variation of atherosclerosis with age. Lab Invest 18 (1968) 571-579
17. Cheruvu P.K., Finn A.V., Gardner C., et al. Frequency and distribution of thin-cap fibroatheroma and ruptured plaques in human coronary arteries: a pathologic study. J Am Coll Cardiol 50 (2007) 940-949
18. Moreno P.R., Purushothaman K.R., Zias E., Sanz J., and Fuster V. Neovascularization in human atherosclerosis. Curr Mol Med 6 (2006) 457-477
19. Ibañez B., Badimon J.J., and Garcia M.J. Diagnosis of atherosclerosis by imaging. Am J Med 122 suppl (2008) S15-S25
20. Stary H.C., Chandler A.B., Dinsmore R.E., et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 92 (1995) 1355-1374
21. Tejada C., Strong J.P., Montenegro M.R., Restrepo C., and Solberg L.A. Distribution of coronary and aortic atherosclerosis by geographic location, race, and sex. Lab Invest 18 (1968) 509-526
22. International Atherosclerosis Project. General findings of the International Atherosclerosis Project. Lab Invest 18 (1968) 498-502
23. Goldstein J.A., Demetriou D., Grines C.L., Pica M., Shoukfeh M., and O'Neill W.W. Multiple complex coronary plaques in patients with acute myocardial infarction. N Engl J Med 343 (2000) 915-922
24. Schoenhagen P., Stone G.W., Nissen S.E., et al. Coronary plaque morphology and frequency of ulceration distant from culprit lesions in patients with unstable and stable presentation. Arterioscler Thromb Vasc Biol 23 (2003) 1895-1900
25. Wang J.C., Normand S.L., Mauri L., and Kuntz R.E. Coronary artery spatial distribution of acute myocardial infarction occlusions. Circulation 110 (2004) 278-284
26. Bays H.E. "Sick fat," metabolic disease, and atherosclerosis. Am J Med 122 suppl (2008) S26-S37
27. Lewis S.J. Prevention and treatment of atherosclerosis: a practitioner's guide for 2008. Am J Med 122 suppl (2008) S38-S50
28. Baigent C., Keech A., Kearney P.M., et al., Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
29. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
30. Sever P.S., Dahlöf B., Poulter N.R., et al., ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361 (2003) 1149-1158
31. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT): major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. JAMA 288 (2002) 2998-3007
32. Crouse III J.R., Raichlen J.S., Riley W.A., et al., METEOR Study Group. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR trial. JAMA 297 (2007) 1344-1353
33. Corti R., Fuster V., Fayad Z.A., et al. Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. J Am Coll Cardiol 46 (2005) 106-112
34. Underhill H.R., Yuan C., Zhao H.Q., et al. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. Am Heart J 155 (2008) 584.e1-584.e8
35. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al., REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291 (2004) 1071-1080
36. Nissen S.E., Nicholls S.J., Sipahi I., et al., ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295 (2006) 1556-1565
37. Nicholls S.J., Tuzcu E.M., Sipahi I., et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 297 (2007) 499-508
38. Saam T., Yuan C., Chu B., et al. Predictors of carotid atherosclerotic plaque progression as measured by noninvasive magnetic resonance imaging. Atherosclerosis 194 (2007) e34-e42
39. Blankenhorn D.H., Selzer R.H., Crawford D.W., et al. Beneficial effects of colestipol-niacin therapy on the common carotid artery: two- and four-year reduction of intima-media thickness measured by ultrasound. Circulation 88 (1993) 20-28
40. Insull W. Effects of statin treatment for regression of carotid atherosclerosis: a literature review of clinical trials analyzing carotid plaques by histopathology. J Clin Lipidol 1 (2007) 371 Abstract 134
41. Libby P., and Aikawa M. Mechanisms of plaque stabilization with statins. Am J Cardiol 91 suppl 4A (2003) 4B-8B
42. Cannon C.P., Braunwald E., McCabe C.H., et al., Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
43. Ray K.K., Cannon C.P., McCabe C.H., et al., PROVE IT-TIMI 22 Investigators. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 46 (2005) 1405-1410
44. Schwartz G.G., Olsson A.G., Ezekowitz M.D., et al., Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL studyA randomized controlled trial. JAMA 285 (2001) 1711-1718
45. Schwartz G., and Singh D. Intensive statin therapy reduces clinical events at 30 days and after six months in acute coronary syndromes. Evid Based Cardiovasc Med 10 (2006) 35-37
46. Ford I., Murray H., Packard C.J., Shepherd J., Macfarlane P.W., Cobbe S.M., et al., West of Scotland Coronary Prevention Study Group. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 357 (2007) 1477-1486
47. Canner P.L., Berge K.G., Wenger N.K., Stamler J., Friedman L., Prineas R.J., and Friedewald W. Fifteen year mortality in the Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 8 (1986) 1245-1255
48. Shepherd J. Cholesterol lowering with statins: how WOSCOPS confounded the skeptics. Atherosclerosis Suppl 8 (2007) 9-12